We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+13.64%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$894M
AUM Growth
-$17.6M
(-1.9%)
Cap. Flow
-$98M
Cap. Flow
% of AUM
-10.96%
Top 10 Holdings %
Top 10 Hldgs %
38.65%
Holding
76
New
8
Increased
23
Reduced
28
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$30.1M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$14M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$11.4M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$9.85M |
| 5 |
ARRY
Array Biopharma Inc
ARRY
|
+$8.51M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$23.5M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$17.6M |
| 3 |
TSRO
TESARO, Inc.
TSRO
|
+$12.9M |
| 4 |
Edwards Lifesciences
EW
|
+$12.5M |
| 5 |
Abbott
ABT
|
+$12.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.98% |
| 2 | Technology | 0.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
| $57.7M | 6.45% |
3,693,690
+288,149
| +8% | +$4.36M |
|
|
AERI
2
DELISTED
Aerie Pharmaceuticals
AERI
| $41.6M | 4.65% |
615,870
+77,252
| +14% | +$4.32M |
|
|
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
| $38.3M | 4.29% |
1,742,622
+94,930
| +6% | +$2.18M |
|
|
LJPC
4
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $38.3M | 4.28% |
1,313,105
+184,886
| +16% | +$5.71M |
|
|
PTLA
5
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $30M | 3.36% |
795,262
+296,850
| +60% | +$11.4M |
|
|
6
Alnylam Pharmaceuticals
ALNY
$35.7B
| $29.9M | 3.34% |
+303,700
| New | +$30.1M |
|
|
EXAS
7
DELISTED
Exact Sciences
EXAS
| $28.6M | 3.2% |
478,649
-95,400
| -17% | -$5.13M |
|
8
Teladoc Health
TDOC
$1.7B
| $27.5M | 3.07% |
473,029
-173,799
| -27% | -$8.49M |
|
9
Sarepta Therapeutics
SRPT
$1.82B
| $27.2M | 3.04% |
205,699
-121,999
| -37% | -$11.5M |
|
10
Collegium Pharmaceutical
COLL
$1.17B
| $26.5M | 2.97% |
1,113,133
-123,401
| -10% | -$3.03M |
|
|
ARRY
11
DELISTED
Array Biopharma Inc
ARRY
| $26.3M | 2.94% |
1,566,477
+534,827
| +52% | +$8.51M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.5B
| $24.5M | 2.74% |
260,505
-137,398
| -35% | -$12M |
|
|
ALXN
13
DELISTED
Alexion Pharmaceuticals
ALXN
| $22.4M | 2.5% |
180,300
+84,300
| +88% | +$9.85M |
|
|
KTWO
14
DELISTED
K2M Group Holdings, Inc
KTWO
| $21.4M | 2.39% |
950,787
-270,373
| -22% | -$5.7M |
|
15
Gilead Sciences
GILD
$167B
| $18.7M | 2.09% |
264,200
+59,200
| +29% | +$4.18M |
|
|
ABMD
16
DELISTED
Abiomed Inc
ABMD
| $18.5M | 2.07% |
45,266
-31,551
| -41% | -$11.4M |
|
17
Pfizer
PFE
$143B
| $17.8M | 1.99% |
516,803
-330,902
| -39% | -$11.3M |
|
18
Molina Healthcare
MOH
$11.7B
| $17.5M | 1.96% |
178,870
+70,800
| +66% | +$6.17M |
|
19
Johnson & Johnson
JNJ
$609B
| $17M | 1.9% |
140,180
-80,768
| -37% | -$10.1M |
|
20
Novartis
NVS
$293B
| $17M | 1.9% |
250,705
-145,805
| -37% | -$10.1M |
|
|
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
| $16.8M | 1.87% |
368,699
+47,900
| +15% | +$2.33M |
|
|
IMMU
22
DELISTED
Immunomedics Inc
IMMU
| $16.5M | 1.84% |
+695,735
| New | +$14M |
|
|
ALDR
23
DELISTED
Alder Biopharmaceuticals
ALDR
| $16.4M | 1.84% |
1,038,900
+175,300
| +20% | +$2.66M |
|
24
Cogent Biosciences
COGT
$6.68B
| $15.5M | 1.74% |
270,386
| – | – |
|
25
UnitedHealth
UNH
$387B
| $15.2M | 1.69% |
61,775
-30,428
| -33% | -$7.31M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q2 2018 Portfolio in Review
As of Q2 2018, Sectoral Asset Management held 76 positions worth $894M, down 1.9% from $912M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Sectoral Asset Management withdrew a net $98M in Q2 2018, closing 9 positions and reducing 28 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $17.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier, followed by Technology.
Against the trend, Sectoral Asset Management opened a new position in Alnylam Pharmaceuticals worth $29.9M.
- Sectoral Asset Management's largest Q2 2018 buy was Alnylam Pharmaceuticals: 303,700 shares worth $29.9M.
- Sectoral Asset Management added most to Portola Pharmaceuticals, Inc. in Q2 2018, an estimated $11.4M increase.
- Sectoral Asset Management's biggest Q2 2018 reduction was Celgene Corp, cutting an estimated $23.5M.
- Sectoral Asset Management fully exited Acadia Pharmaceuticals in Q2 2018, selling an estimated $17.6M.
- Sectoral Asset Management's ten largest holdings make up 39% of its $894M portfolio in Q2 2018.
- Sectoral Asset Management opened 8 new positions and closed 9 in Q2 2018.
- Sectoral Asset Management's portfolio value fell 1.9% quarter-over-quarter to $894M.
Based on Sectoral Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.